Antiphospholipid antibodies and the antiphospholipid syndrome: An update on treatment and pathogenic mechanisms

Silvia S. Pierangeli, Pojen P. Chen, Emilio Gonzalez

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The antiphospholipid syndrome is a disorder of recurrent thrombosis, pregnancy loss and thrombocytopenia associated with the presence of antiphospholipid antibodies and persistently positive anticardiolipin or lupus anticoagulant positive tests. Since its recognition in the 1980s, growing interest in the field, not only with respect to diagnosis and treatment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged. RECENT FINDINGS: First, this review addresses the recently updated classification criteria for diagnosis and treatment of the antiphospholipid syndrome. A discussion on the newly described potential beneficial roles of hydroxychloroquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestations is included. Importantly, this article analyzes recent data that examine the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as well as new findings in the identification of the receptors for these antibodies on the membrane of those cells. A separate section discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of complement and their interaction with homologous catalytic domains of several serine proteases of the coagulation system. SUMMARY: Understanding the molecular interactions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and targeted strategies to ameliorate clinical manifestations in patients with antiphospholipid syndrome may be established.

Original languageEnglish (US)
Pages (from-to)366-375
Number of pages10
JournalCurrent Opinion in Hematology
Volume13
Issue number5
DOIs
StatePublished - Sep 2006

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Hydroxychloroquine
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lupus Coagulation Inhibitor
Complement Activation
Serine Proteases
Thrombocytopenia
Catalytic Domain
Thrombosis
Cell Membrane
Pregnancy
Antibodies

Keywords

  • Antiphospholipid antibodies
  • Complement activation
  • Intracellular signalling
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Antiphospholipid antibodies and the antiphospholipid syndrome : An update on treatment and pathogenic mechanisms. / Pierangeli, Silvia S.; Chen, Pojen P.; Gonzalez, Emilio.

In: Current Opinion in Hematology, Vol. 13, No. 5, 09.2006, p. 366-375.

Research output: Contribution to journalArticle

@article{6edbbed75f484da89df2daa98fcc2f1f,
title = "Antiphospholipid antibodies and the antiphospholipid syndrome: An update on treatment and pathogenic mechanisms",
abstract = "PURPOSE OF REVIEW: The antiphospholipid syndrome is a disorder of recurrent thrombosis, pregnancy loss and thrombocytopenia associated with the presence of antiphospholipid antibodies and persistently positive anticardiolipin or lupus anticoagulant positive tests. Since its recognition in the 1980s, growing interest in the field, not only with respect to diagnosis and treatment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged. RECENT FINDINGS: First, this review addresses the recently updated classification criteria for diagnosis and treatment of the antiphospholipid syndrome. A discussion on the newly described potential beneficial roles of hydroxychloroquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestations is included. Importantly, this article analyzes recent data that examine the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as well as new findings in the identification of the receptors for these antibodies on the membrane of those cells. A separate section discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of complement and their interaction with homologous catalytic domains of several serine proteases of the coagulation system. SUMMARY: Understanding the molecular interactions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and targeted strategies to ameliorate clinical manifestations in patients with antiphospholipid syndrome may be established.",
keywords = "Antiphospholipid antibodies, Complement activation, Intracellular signalling, Thrombosis",
author = "Pierangeli, {Silvia S.} and Chen, {Pojen P.} and Emilio Gonzalez",
year = "2006",
month = "9",
doi = "10.1097/01.moh.0000239710.47921.d2",
language = "English (US)",
volume = "13",
pages = "366--375",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Antiphospholipid antibodies and the antiphospholipid syndrome

T2 - An update on treatment and pathogenic mechanisms

AU - Pierangeli, Silvia S.

AU - Chen, Pojen P.

AU - Gonzalez, Emilio

PY - 2006/9

Y1 - 2006/9

N2 - PURPOSE OF REVIEW: The antiphospholipid syndrome is a disorder of recurrent thrombosis, pregnancy loss and thrombocytopenia associated with the presence of antiphospholipid antibodies and persistently positive anticardiolipin or lupus anticoagulant positive tests. Since its recognition in the 1980s, growing interest in the field, not only with respect to diagnosis and treatment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged. RECENT FINDINGS: First, this review addresses the recently updated classification criteria for diagnosis and treatment of the antiphospholipid syndrome. A discussion on the newly described potential beneficial roles of hydroxychloroquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestations is included. Importantly, this article analyzes recent data that examine the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as well as new findings in the identification of the receptors for these antibodies on the membrane of those cells. A separate section discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of complement and their interaction with homologous catalytic domains of several serine proteases of the coagulation system. SUMMARY: Understanding the molecular interactions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and targeted strategies to ameliorate clinical manifestations in patients with antiphospholipid syndrome may be established.

AB - PURPOSE OF REVIEW: The antiphospholipid syndrome is a disorder of recurrent thrombosis, pregnancy loss and thrombocytopenia associated with the presence of antiphospholipid antibodies and persistently positive anticardiolipin or lupus anticoagulant positive tests. Since its recognition in the 1980s, growing interest in the field, not only with respect to diagnosis and treatment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged. RECENT FINDINGS: First, this review addresses the recently updated classification criteria for diagnosis and treatment of the antiphospholipid syndrome. A discussion on the newly described potential beneficial roles of hydroxychloroquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestations is included. Importantly, this article analyzes recent data that examine the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as well as new findings in the identification of the receptors for these antibodies on the membrane of those cells. A separate section discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of complement and their interaction with homologous catalytic domains of several serine proteases of the coagulation system. SUMMARY: Understanding the molecular interactions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and targeted strategies to ameliorate clinical manifestations in patients with antiphospholipid syndrome may be established.

KW - Antiphospholipid antibodies

KW - Complement activation

KW - Intracellular signalling

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=33746741718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746741718&partnerID=8YFLogxK

U2 - 10.1097/01.moh.0000239710.47921.d2

DO - 10.1097/01.moh.0000239710.47921.d2

M3 - Article

C2 - 16888443

AN - SCOPUS:33746741718

VL - 13

SP - 366

EP - 375

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 5

ER -